Advertisement

Nonalcoholic Fatty Liver Disease: Clinical Features, Disease Modifiers, and Natural History

  • Dawn M. Torres
  • Stephen A. HarrisonEmail author

Abstract

Nonalcoholic fatty liver disease (NAFLD) typically presents as an asymptomatic elevation of liver-associated enzymes and has been associated with a number of clinical conditions that are included in the definition of the metabolic syndrome such as obesity, hyperlipidemia, and insulin resistance. NAFLD also has been shown to be related to a variety of conditions such as cardiovascular disease and obstructive sleep apnea. This review will address the clinical presentation and natural history of NAFLD as the hepatic manifestation of the metabolic syndrome.

Keywords

NAFLD Natural history Steatohepatitis Obstructive sleep apnea Diabetes mellitus Obesity 

Notes

Disclaimer

The opinion or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the view of the US Department of the Army or the US Department of Defense.

Grant Support

None.

References

  1. 1.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10:837–58.CrossRefPubMedGoogle Scholar
  3. 3.
    Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95.CrossRefPubMedGoogle Scholar
  4. 4.
    Younossi Z, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the US. Medicine (Baltimore). 2012;91:319–27.CrossRefGoogle Scholar
  5. 5.
    Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013;28 Suppl 1:11–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Cheung O, Kapoor A, Puri P, et al. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology. 2007;46:1091–100.CrossRefPubMedGoogle Scholar
  7. 7.
    Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Mofrad P, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–92.CrossRefPubMedGoogle Scholar
  9. 9.
    Pantsari MW, Harrison SA. Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase. J Clin Gastroenterol. 2006;40:633–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Adams L, Lindo K, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2004;99:1316–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Kowdley KV, Belt P, Wilson LA. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:77–85.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Bugianesi E, et al. Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179–87.CrossRefPubMedGoogle Scholar
  13. 13.
    Adams LA, Crawford D, Stuart K, et al. The impact of phlebotomy in nonalcoholic fatty liver disease: a prospective randomized controlled trial. Hepatology. 2015;61(5):1555–64. doi: 10.1002/hep.27662.CrossRefPubMedGoogle Scholar
  14. 14.
    Facchini F, Hua N, Stoohs R. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology. 2002;122:931–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Valenti L, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol. 2007;101:1251–8.CrossRefGoogle Scholar
  16. 16.
    Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease in type 2 diabetic patients. Diabetes Care. 2007;30:1212–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Fan JG, Li F, Cai XB, et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol. 2007;22:1086–91.CrossRefPubMedGoogle Scholar
  18. 18.
    Ortiz-Lopez C, Lomonaco R, Orsak B, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with NAFLD. Diabetes Care. 2012;35:873–8.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Adams LA, Harmsen S. St. Sauver JL et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010;105:1567–73.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetes patients. Diabetologia. 2008;51:444–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Casserta CA, Pendino GM, Amante A, et al. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am J Epidemiol. 2010;171:1195–202.CrossRefGoogle Scholar
  22. 22.
    Musso G. The Finnish Diabetes Risk Score (FINDRISC) and other non-invasive scores for screening hepatic steatosis and associated cardiometabolic risk. Ann Intern Med. 2011;43:413–7.CrossRefGoogle Scholar
  23. 23.
    Petta S, Argano C, Columba D, et al. Epicardial fat, cardiac geometry and cardiac function in patients with nonalcoholic fatty liver disease: association with severity of liver disease. J Hepatol. 2015;62(4):928–33.CrossRefPubMedGoogle Scholar
  24. 24.
    Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol. 2014;20(26):8407–15.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Vanwagner LB, Bhave M, Te HS, et al. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012;56(5):1741–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Ram S, Seirawan H, Kumar SK, Clark GT. Prevalence and impact of sleep disorders and sleep habits in the United States. Sleep Breath. 2010;14(1):63–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Hiestand DM, Britz P, Goldman M, Phillips B. Prevalence of symptoms and risk of sleep apnea in the US population: results from the national sleep foundation sleep in America 2005 poll. Chest. 2006;130(3):780–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Daltro C, Cotrim HP, Alves E, et al. Nonalcoholic fatty liver disease associated with obstructive sleep apnea: just a coincidence? Obes Surg. 2010;20:1536–43.CrossRefPubMedGoogle Scholar
  29. 29.
    Lin QC, Chen LD, Chen GP, et al. Association between nocturnal hypoxia and liver injury in the setting of nonalcoholic fatty liver disease. Sleep Breath. 2015;19(1):273–80.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Aron-Wisnewsky J, Minville C, Tordjman J, et al. Chronic intermittent hypoxia is a major trigger for nonalcoholic fatty liver disease in morbid obese. J Hepatol. 2012;56:225–33.CrossRefPubMedGoogle Scholar
  31. 31.
    Sundaram SS, Sokol RJ, Capocelli KE, et al. Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease. J Pediatr. 2014;164(4):699–706.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Chin K, Nakamura T, Takahashi K, et al. Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. Am J Med. 2003;114:370–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Kohler M, Pepperell JC, Davies RJ, Stradling JR. Continuous positive airway pressure and liver enzymes in obstructive sleep apnoea: data from a randomized controlled trial. Respiration. 2009;78(2):141–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;292:2038–47.CrossRefGoogle Scholar
  35. 35.
    Zhang L, Zhang P, Wang F, et al. Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis. 2008;51:373–84.CrossRefPubMedGoogle Scholar
  36. 36.
    Armstrong MJ, Adams LA, Canbay A, Syn WK. Extra-hepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174–97.CrossRefPubMedGoogle Scholar
  37. 37.
    Sirota JC, McFann K, Targer G, et al. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988–1994. Am J Nephrol. 2012;36(5):466–71.PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001–2006. Nutr Metab Cardiovasc Dis. 2010;20(8):583–90.CrossRefPubMedGoogle Scholar
  39. 39.
    Yilmaz Y, Alahdab YO, Yonal O, et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism. 2010;59:1327–30.CrossRefPubMedGoogle Scholar
  40. 40.
    Targher G, Bertolini L, Rodella S, et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5:2166–71.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Yasui K, Sumida Y, Mori Y, et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism. 2011;60:735–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Musso G, Gambino R, Tabibian JH, et al. Association of nonalcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7), e1001680. doi:10.1371/journal.pmed.1001680. eCollection 2014.PubMedCentralCrossRefPubMedGoogle Scholar
  43. 43.
    Lee DH, Jacobs DR, Gross M, et al. Serum GGT was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin Chem. 2005;51:1185–91.CrossRefPubMedGoogle Scholar
  44. 44.
    Lee DS, Evans JC, Robins SJ, et al. GGT and metabolic syndrome, cardiovascular disease and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:127–33.CrossRefPubMedGoogle Scholar
  45. 45.
    Ryu S, Chang Y, Kim DI, et al. GGT as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem. 2007;53:71–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Chang Y, Ryu S, Sung E, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008;57:569–76.CrossRefPubMedGoogle Scholar
  47. 47.
    Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564–70.PubMedCentralCrossRefPubMedGoogle Scholar
  48. 48.
    Musso G, Tabibian JH, Charlton M, et al. Chronic kidney disease (CKD) and NAFLD: time for hepatologists for awareness and screening. J Hepatol. 2015;62(4):983–4.CrossRefPubMedGoogle Scholar
  49. 49.
    Allen AM, Kim WR, Therneau TM. Chronic kidney disease and associated mortality after liver transplantation-a time-dependent analysis using measured glomerular filtration rate. J Hepatol. 2014;61(2):286–92.PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    Kwok RM, Torres DM, Harrison SA. Vitamin D and NAFLD: is it more than just an association. Hepatology. 2013;58:1166–74.CrossRefPubMedGoogle Scholar
  51. 51.
    Liangpunsakul S, Chalasani N. Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci. 2011;56:2124–9.PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Barchetta I, Angelico F, Del Ben M, et al. Strong association between nonalcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011;9:85.PubMedCentralCrossRefPubMedGoogle Scholar
  53. 53.
    Targer G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007;17:517–24.CrossRefGoogle Scholar
  54. 54.
    Bril F, Maximos M, Portillo-Sanchez P. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. J Hepatol. 2015;62(2):405–11.CrossRefPubMedGoogle Scholar
  55. 55.
    Moon SS, Lee YS, Kim SW. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine. 2012;42:4423–9.CrossRefGoogle Scholar
  56. 56.
    Li M, Xu Y, Xu M, et al. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab. 2012;97:2033–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Pardee PE, Dunn W, Schwimmer JB. Nonalcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment Pharmacol Ther. 2012;35:248–54.PubMedCentralCrossRefPubMedGoogle Scholar
  58. 58.
    Hwang ST, Cho YK, Park JH, et al. Relationship of nonalcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol. 2010;25:562–7.CrossRefPubMedGoogle Scholar
  59. 59.
    Wong VW, Wong GL, Tsang SW, et al. High prevalence of colorectal neoplasm in patients with nonalcoholic steatohepatitis. Gut. 2011;60:829–36.CrossRefPubMedGoogle Scholar
  60. 60.
    Touzin NT, Bush KN, Williams CD, et al. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2011;4:169–76.PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Min YW, Yun HS, Change WI, et al. Influence of non-alcoholic fatty liver disease on the prognosis in patients with colorectal cancer. Clin Res Hepatol Gastroenterol. 2012;36(1):78–83.CrossRefPubMedGoogle Scholar
  62. 62.
    Tock L, Carneiro G, Togeiro SM, et al. Obstructive sleep apnea predisposed to nonalcoholic fatty liver disease in patients with polycystic ovary syndrome. Endocr Pract. 2014;20(3):244–51.CrossRefPubMedGoogle Scholar
  63. 63.
    Barfield E, Liu YH, Kessler M. The prevalence of abnormal liver enzymes and metabolic syndrome in obese adolescent female with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2009;22(5):318–22.CrossRefPubMedGoogle Scholar
  64. 64.
    Zueff LFN, Martins WP, Vieira CS, et al. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovarian syndrome. Ultrasound Obstet Gynecol. 2012;39:341–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Brzozowska MM, Ostapowicz G, Weltman MD. An association between nonalcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol. 2009;24:243–7.CrossRefPubMedGoogle Scholar
  66. 66.
    Pagadala MR, Zein CO, Dasarathy S, et al. Prevalence of hypothyroidism in NAFLD. Dig Dis Sci. 2012;57:528–34.PubMedCentralCrossRefPubMedGoogle Scholar
  67. 67.
    Chung GE, Kim D, Kim W, et al. Nonalcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol. 2012;57:150–6.CrossRefPubMedGoogle Scholar
  68. 68.
    Liu PJ, Ma F, Lou HP, et al. Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women. Climacteric. 2014;17(6):692–9.CrossRefPubMedGoogle Scholar
  69. 69.
    Sertoglu E, Ercin CN, Celebi G. The relationship of serum uric acid with nonalcoholic fatty liver disease. Clin Biochem. 2014;47(6):383–8.CrossRefPubMedGoogle Scholar
  70. 70.
    Teli M, et al. The natural history of nonalcoholic fatty liver disease: a follow-up study. Hepatology. 1995;22(6):1714–9.CrossRefPubMedGoogle Scholar
  71. 71.
    Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1416–9.CrossRefGoogle Scholar
  72. 72.
    Dam-Larsen S, Becker U, Franzmann MG, et al. Final results of a long-term, clinical follow-up of fatty liver patients. Scand J Gastroenterol. 2009;44:1236–43.CrossRefPubMedGoogle Scholar
  73. 73.
    Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28 year follow-up period. Hepatology. 2010;51:595–602.CrossRefPubMedGoogle Scholar
  74. 74.
    Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31.CrossRefPubMedGoogle Scholar
  75. 75.
    McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis & clinical management. J Hepatol. 2015;62(5):1148–55. doi: 10.1016/j.jhep.2014.11.034. pii: S0168-8278(14)00883-6.CrossRefPubMedGoogle Scholar
  76. 76.
    Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver versus nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–54. e9.CrossRefPubMedGoogle Scholar
  77. 77.
    Harrison SA. Nonalcoholic liver disease and fibrosis progression: the good, the bad, and the unknown. Clin Gastroenterol Hepatol. 2015;13(4):655–7.CrossRefPubMedGoogle Scholar
  78. 78.
    Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver disease. J Hepatol. 2013;59(3):550–6.CrossRefPubMedGoogle Scholar
  79. 79.
    Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42(1):132–8.CrossRefPubMedGoogle Scholar
  80. 80.
    Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver related mortality. Hepatology. 2011;58:1874–82.CrossRefGoogle Scholar
  81. 81.
    Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–54. doi: 10.1002/hep.27368.CrossRefPubMedGoogle Scholar
  82. 82.
    Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. Hepatology. 2005;42:132–8.CrossRefGoogle Scholar
  83. 83.
    Zein CO, Unalp A, Colvin R, et al. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011;54:753–9.PubMedCentralCrossRefPubMedGoogle Scholar
  84. 84.
    Angulo P. Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts. Hepatology. 2011;53:1792–4.CrossRefPubMedGoogle Scholar
  85. 85.
    Cortez-Pinto H, et al. Nonalcoholic steatohepatitis-a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci. 2003;48:1909–13.CrossRefPubMedGoogle Scholar
  86. 86.
    Poonawala A, Nair S, Thuluvath P, et al. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32:689–92.CrossRefPubMedGoogle Scholar
  87. 87.
    Marrero J, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36:1349–54.CrossRefPubMedGoogle Scholar
  88. 88.
    Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology. 2014;59(6):2188–95.CrossRefPubMedGoogle Scholar
  89. 89.
    Hui J, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38:420–7.CrossRefPubMedGoogle Scholar
  90. 90.
    Charlton MR, Burns JM, Pederson RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–53.CrossRefPubMedGoogle Scholar
  91. 91.
    O’Leary JG, Landaverde C, Jennings L, et al. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol. 2011;9:700–4.PubMedCentralCrossRefPubMedGoogle Scholar
  92. 92.
    Barritt AS, Dellon ES, Kozlowski T, et al. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol. 2011;45:372–8.PubMedCentralCrossRefPubMedGoogle Scholar
  93. 93.
    Yalamanchili K, Saadeh S, Klintman GB, et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010;16:431–9.PubMedGoogle Scholar
  94. 94.
    Vallin M, Guillaud O, Boillot O, et al. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis. Liver Transpl. 2014;20:1064–71.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Division of Gastroenterology, Department of MedicineWalter Reed National Military Medical CenterBethesdaUSA
  2. 2.Division of Gastroenterology and Hepatology, Department of MedicineSan Antonio Military Medical CenterFort Sam HoustonUSA

Personalised recommendations